Navigation Links
EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX, is scheduled to present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, July 10, 2007 at 1:30 p.m. (EDT) at the Mandarin Oriental Hotel in New York, NY.

The presentation will be webcast live and can be accessed on the EPIX website, www.epixpharma.com, in the investor relations section. A replay will be available approximately twenty-four hours after the presentation and will be archived on the company's website for two weeks.

About EPIX

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in development for conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, PRX-03140 which is in a Phase 2a clinical trial in Alzheimer's disease, PRX-00023 which is in a Phase 2b clinical trial in major depressive disorder, and PRX-07034, which recently completed a Phase 1b trial and is in clinical development for the treatment of obesity and cognitive impairment. The company also has a blood-pool imaging agent (Vasovist(TM)) approved in 32 countries and marketed in Europe. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics, and Bayer Schering Pharma AG, Germany. For more information, please visit the company's website at www.epixpharma.com.

This news release contains expres s or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q.

Contact

EPIX
Kim C. Drapkin, 781-761-7602
Chief Financial Officer
or
Pure Communications
Stacey Fisher, 305-335-9577


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2020)... ... 2020 , ... In order to provide continuous patient care ... addition to in-person visits. The San Diego-based leader in regenerative health therapies made ... professionals, and the community at large is the top priority. , Aspire ...
(Date:3/28/2020)... ... March 27, 2020 , ... ... International has named Gary Gallant as its permanent CIO. In this executive ... technology vision, ensuring Isagenix can provide a smooth shopping experience for customers and ...
(Date:3/27/2020)... ... March 27, 2020 , ... Why a Podcast for Procap Medical Billing? , ... because she’d be able to explain more about what her business entails on a ... to learn more about the process of claim follow-up, conversing and networking with health ...
Breaking Medicine Technology:
(Date:4/2/2020)... ... , ... Since the onset of the COVID-19 pandemic, there hasn’t yet been ... https://www.goparrot.ai/ ) founder Yaniv Nissim has stepped up to the plate to address this ... created new standards for delivering food during this time of COVID-19 so that consumers ...
(Date:4/1/2020)... WASHINGTON (PRWEB) , ... April 01, 2020 , ... According ... women of reproductive age (13-44) in need of publicly funded contraception live in ... rule.” Nearly one-quarter of Minnesota’s counties have lost some or all of their Title ...
(Date:4/1/2020)... , ... April 01, 2020 , ... ... private of information under California law,” says Keller Grover LLP attorney Eric A. ... notice of data breaches and the negligent release and disclosure of medical information ...
(Date:3/28/2020)... ... March 27, 2020 , ... With social distancing, ... grow by the day, people of all ages are challenged to find different ... social interactions in the best of times—the physical distance mandated to prevent the ...
(Date:3/28/2020)... ... March 28, 2020 , ... iPatientCare, a pioneer in cloud-based ... engagement solutions has expanded the availability of telehealth services and other initiatives to ... telemedicine has a big role in fighting coronavirus . Increasing the telehealth services ...
Breaking Medicine News(10 mins):